Evidence map›Paper›PMID 39821533›Full record

ReviewCurrent hypertension reports2025

Approach to Endocrine Hypertension: A Case-Based Discussion.

Sanja Borozan, A B M Kamrul-Hasan, Sahana Shetty, Joseph M Pappachan

Abstract readReviewCase Reports
In one paragraph

Review in Current hypertension reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sanja BorozanDepartment of Endocrinology, Clinical Centre of Montenegro, Podgorica, Montenegro.ORCID http://orcid.org/0009-0001-2042-4359
A B M Kamrul-HasanMymensingh Medical College, Mymensingh, Bangladesh.ORCID http://orcid.org/0000-0002-5681-6522
Sahana ShettyDepartment of Endocrinology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, 576104, India.
Joseph M PappachanDepartment of Endocrinology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, 576104, India. drpappachan@yahoo.co.in.ORCID http://orcid.org/0000-0003-0886-5255

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewHypertension remains a major chronic disease morbidity across the world, even in the twenty-first century, affecting ≈40% of the global population, adversely impacting the healthcare budgets in managing the high incidence of cardiovascular disease (CVD) complications and mortality because of elevated blood pressure (BP). However, evaluation and management of endocrine hypertension are not optimal in clinical practice. With three unique clinical case scenarios, we update the evidence base for diagnostic evaluation and management of endocrine hypertension in this review to inform appropriate day-to-day clinical practice decisions. RECENT

findingsAlthough most individuals with high BP suffer from essential hypertension (≈85%), some patients may have a clear underlying etiology (termed secondary hypertension), and a significant proportion of these patients have endocrine hypertension (≈10%) consequent to hormone excess from dysfunction of one or more endocrine glands. Even if a relatively common disease in the general population, the correct diagnosis and appropriate treatment of endocrine hypertension is often delayed because of poor awareness among clinicians, including primary care providers and physicians in the secondary care settings. An accurate and timely diagnosis of endocrine hypertension is crucial to potentially cure or at least properly manage these patients because the consequences of delays in diagnosis can be catastrophic, with markedly higher end-organ complications such as CVD, chronic kidney disease, and even premature mortality among sufferers.

Indexed as

Endocrine System DiseasesHypertensionAntihypertensive AgentsFemaleHumansMaleMiddle AgedAntihypertensive AgentsAcromegalyAldosterone renin ratioCushing syndromeEndocrine hypertensionPheochromocytomaPrimary aldosteronismResistant hypertension

Identifiers

PMID39821533
PMCPMC11739263

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.